There are currently 1129 clinical trials in Cincinnati, Ohio looking for participants to engage in research studies. Trials are conducted at various facilities, including Cincinnati Children's Hospital Medical Center, University of Cincinnati, University of Cincinnati Medical Center and GSK Investigational Site. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Registry of Asthma Characterization and Recruitment 3 (RACR3)
NCT05272241
Recruiting
This is a multi-center, non-interventional registry to create and maintain a database of participants to serve as a recruitment source for current and future DAIT NIAID-sponsored Childhood Asthma in Urban Settings (CAUSE) studies.
Gender:
ALL
Ages:
All
Trial Updated:
06/17/2025
Locations: Cincinnati Children's Hospital Medical Center: Asthma Center, Cincinnati, Ohio
Conditions: Asthma
Register for Updates
A Clinical Study of Pembrolizumab (+) Berahyaluronidase Alfa (MK-3475A) to Treat Newly-diagnosed Metastatic Non-small Cell Lung Cancer (MK-3475A-F84)
NCT06698042
Recruiting
Researchers are looking for new ways to treat non-small cell lung cancer (NSCLC) that is metastatic, which means cancer has spread to other parts of the body. Some people with metastatic NSCLC are treated with pembrolizumab, an immunotherapy treatment that is given into a vein as an intravenous (IV) infusion. Pembrolizumab (+) Berahyaluronidase alfa is pembrolizumab that is given under the skin as a subcutaneous (SC) injection. The goal of this study is to compare what happens to pembrolizumab... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/17/2025
Locations: University of Cincinnati Medical Center ( Site 0112), Cincinnati, Ohio
Conditions: Lung Cancer, Non-Small Cell Lung Cancer
Register for Updates
A proof-of Concept Study to Assess Safety and Tolerability of HM15421/GC1134A in Patients With Fabry Disease
NCT06858397
Recruiting
This Phase 1/2 first-in-human (FIH) study is designed to evaluate the safety, tolerability, pharmacokinetics (PK), and efficacy of HM15421 in patients with FD.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/17/2025
Locations: Children's Hospital Medical Center, Cincinnati, Ohio
Conditions: Fabry Disesase
Register for Updates
Trial to Evaluate Safety And Effectiveness of Mechanical Circulatory Support in Patients With Advancing Heart Failure
NCT06526195
Recruiting
The purpose of TEAM-HF IDE clinical trial is to evaluate safety and effectiveness of the HeartMate 3 LVAS compared to guideline directed medical therapy (GDMT) in a population of ambulatory advanced heart failure patients who are not dependent on intravenous inotrope.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/17/2025
Locations: Christ Hospital, Cincinnati, Ohio
Conditions: Heart Failure, Heart Diseases, Cardiovascular Diseases, Pulmonary Hypertension
Register for Updates
A Study With Eptinezumab in Children and Adolescents (6 to 17 Years) With Chronic or Episodic Migraine
NCT05164172
Recruiting
The main goal of the study is to assess the long-term safety of eptinezumab on children and adolescents ages 6 to 17 with chronic or episodic migraine.
Gender:
ALL
Ages:
Between 6 years and 17 years
Trial Updated:
06/17/2025
Locations: Cincinnati Children's Hospital Medical Center - PIN, Cincinnati, Ohio
Conditions: Migraine
Register for Updates
Antibiotic Cement Bead Pouch Versus Negative Pressure Wound Therapy
NCT05615844
Recruiting
The Beads vs Vac trial is a multi-centre randomized controlled trial of 312 participants with a severe open tibia fracture requiring multiple irrigation and debridement surgeries. Eligible participants will be randomized to receive either an antibiotic bead pouch or negative pressure wound therapy (NPWT) for their temporary open fracture wound management. Outcomes will be assessed at 6 weeks, 3 months, and 6 months post-surgery. The primary outcome will be a composite outcome to evaluate clinica... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/17/2025
Locations: University of Cincinnati, Cincinnati, Ohio +1 locations
Conditions: Open tíbia Fracture
Register for Updates
P-CD19CD20-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With B Cell Malignancies
NCT06014762
Recruiting
Phase 1 study comprised of open-label, dose escalation and expansion cohort study of P-CD19CD20-ALLO1 allogeneic T stem cell memory (Tscm) CAR-T cells in subjects with relapsed/refractory B cell malignancies
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/17/2025
Locations: University of Cincinnati, Cincinnati, Ohio
Conditions: Primary Mediastinal Large B-cell Lymphoma (PMBCL), Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, High-grade B-cell Lymphoma, Transformed Follicular Lymphoma (tFL), Follicular Lymphoma Grade 3B, DLBCL, DLBCL - Diffuse Large B Cell Lymphoma, DLBCL Arising From Follicular Lymphoma, DLBCL, Diffused Large B Cell Lymphoma, DLBCL NOS
Register for Updates
P-BCMA-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Multiple Myeloma
NCT04960579
Recruiting
Phase 1 study comprised of open-label, dose escalation, multiple cohorts of P-BCMA-ALLO1 allogeneic T stem cell memory (Tscm) CAR-T cells in subjects with relapsed / refractory Multiple Myeloma (RRMM).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/17/2025
Locations: University of Cincinnati, Cincinnati, Ohio
Conditions: Multiple Myeloma
Register for Updates
Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer
NCT05445778
Recruiting
GLORIOSA is a Phase 3 multicenter, open label study designed to evaluate the safety and efficacy of mirvetuximab Soravtansine + Bevacizumab as maintenance therapy in participants with platinum-sensitive ovarian, primary peritoneal or fallopian tube cancers with high folate receptor-alpha (FRα) expression.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
06/17/2025
Locations: University of Cincinnati /ID# 269578, Cincinnati, Ohio
Conditions: Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer
Register for Updates
A Study to Learn How Well Dupilumab Works in Adult and Adolescent Participants With Eosinophilic Gastritis With or Without Eosinophilic Duodenitis and the Side Effects it May Have
NCT05831176
Recruiting
This study is researching an experimental drug called dupilumab. The study is focused on participants with active eosinophilic gastritis (EoG) with or without eosinophilic duodenitis (EoD). Participants with EoD only are not eligible for enrollment. EoG and EoD are uncommon, persistent, allergic/immune diseases in which eosinophils (a type of white blood cell) gather in large numbers in the stomach and small intestine and cause inflammation and damage. The aim of the study is to evaluate the ef... Read More
Gender:
ALL
Ages:
12 years and above
Trial Updated:
06/17/2025
Locations: University of Cincinnati Medical Center-Children's Hospital Medical Center, Cincinnati, Ohio
Conditions: Eosinophilic Gastritis (EoG), Eosinophilic Duodenitis (EoD), Eosinophilic Gastrointestinal Disease (EGID), Eosinophilic Gastroenteritis
Register for Updates
A Research Study Comparing How Well Different Doses of the Medicine NN0519-0130 Lower Blood Sugar in People With Type 2 Diabetes
NCT06326047
Recruiting
This study will look at how well a new medicine called NNC0519-0130 helps people with type 2 diabetes lower their blood sugar and body weight. The study will test up to 7 different doses of NNC0519-0130. Which treatment participant will get is decided by chance. Participants will take 1-3 injections once a week. The study medicine will be injected under skin with a thin needle in the stomach, thigh, or upper arm. The study will last for about 40 weeks.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
06/17/2025
Locations: Velocity Clin Res_Cincinnati, Cincinnati, Ohio +3 locations
Conditions: Diabetes Mellitus, Type 2
Register for Updates
A Study With Eptinezumab in Adolescents (12-17 Years) With Chronic Migraine
NCT04965675
Recruiting
To find out if eptinezumab is better than placebo (normal saline solution) in lowering the number of days with migraine in young people ages 12 to 17 with chronic migraine.
Gender:
ALL
Ages:
Between 12 years and 17 years
Trial Updated:
06/17/2025
Locations: Cincinnati Children's Hospital Medical Center - PIN, Cincinnati, Ohio
Conditions: Chronic Migraine in Children
Register for Updates